Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC-4/RTOG-3515: Durvalumab with SBRT in unresected stage I/II NSCLC
2018-002572-41Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Dec 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + SBRT, Placebo + SBRT and Osimertinib cohort (3 arms). Started Dec 2018; status: active.
02
Drugs
durvalumabosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-002572-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002572-41.